SCHEDULE 13G/A: L1 Capital Global Opportunities Master Fund Discloses 6.22% Stake in ENDRA Life Sciences

L1 Capital Global Opportunities Master Fund, Ltd. has filed an amended Schedule 13G, disclosing a 6.22% beneficial ownership stake in ENDRA Life Sciences Inc. as of December 31, 2024.

Summary

• L1 Capital Global Opportunities Master Fund, Ltd. reported beneficial ownership of 35,589 shares of ENDRA Life Sciences Inc. Common Stock.
• This beneficial ownership represents 6.22% of the outstanding Common Stock of ENDRA Life Sciences Inc.
• The reported ownership is primarily derived from Common Stock underlying warrants, which are subject to a 9.99% beneficial ownership limitation.
• The percentage calculation is based on 536,908 shares of Common Stock outstanding for ENDRA Life Sciences Inc. as of November 19, 2024, as reported in the Issuer's Amendment No. 1 to Form 10-Q/A.
• This filing is an Amendment No. 1 to a previous Schedule 13G filed on June 14, 2024, which covered 7,921,648 shares of Common Stock and underlying Warrants purchased on June 4, 2024.

Sentiment

Score: 4

Explanation: While the filing is a routine disclosure, the significant reduction in the absolute number of shares held by the reporting person compared to a prior filing, even if due to a reverse stock split, could be perceived negatively as it represents a smaller absolute investment by the fund.

Positives

• L1 Capital Global Opportunities Master Fund, Ltd. maintains a significant beneficial ownership stake of 6.22% in ENDRA Life Sciences Inc., indicating continued institutional investor interest.

Negatives

• The reported beneficial ownership of 35,589 shares represents a substantial reduction in absolute share count compared to the 7,921,648 shares reported in the previous Schedule 13G filing on June 14, 2024, likely due to a reverse stock split by ENDRA Life Sciences Inc. or a significant divestment by the fund.

Risks

• The significant reduction in the absolute number of shares held by L1 Capital Global Opportunities Master Fund, Ltd. (from 7,921,648 to 35,589) could indicate a strategic divestment or a lack of confidence, potentially signaling future share price volatility for ENDRA Life Sciences Inc.
• The beneficial ownership is primarily derived from warrants, which may introduce dilution risk if exercised, depending on the strike price relative to the market price.
• The 9.99% beneficial ownership limitation on warrants could restrict the fund's ability to increase its stake beyond a certain threshold without further disclosures or actions.

Future Outlook

NA

Management Comments

• "The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11." (from David Feldman, Director of L1 Capital Global Opportunities Master Fund, Ltd.)

Industry Context

This Schedule 13G filing reflects a change in beneficial ownership for ENDRA Life Sciences Inc., a company operating in the life sciences sector. Such filings are standard disclosures for significant equity stakes and do not inherently provide broader industry context or trends, beyond indicating investor activity within the sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant beneficial ownership stake by an institutional investor can influence investor perception and potentially share price. The substantial reduction in absolute shares held by the fund might raise questions among existing shareholders regarding the fund's long-term commitment or the company's underlying value.

Key Dates

Keywords

ENDRA Life Sciences, L1 Capital, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, SEC Filing, Investment Fund, Shareholding, Equity Stake